Precision medicine starts here
|18th May 2018
Precision medicine is set to revolutionise the healthcare sector, promising vastly improved outcomes for patients. However, as treatments become more precise, pharma companies will need to create more targeted commercial strategies. Meanwhile, the clinical trial recruitment process will become more challenging and a new series of stakeholders will emerge. These are just some of the barriers.
That’s why have dedicated the latest edition of our ‘Perspective’ magazine to this complex topic. We have combined the views of our in-house precision medicine experts and voices from key industry leaders to give you the latest information on the trend set to redefine healthcare as we know it – precision medicine.
In this edition of ‘Perspective’, we answer the following questions:
- Are we ready for precision medicine?
- How can you master the precision medicine opportunity?
- How can industry drive greater engagement in the clinical trial recruitment process?
- Will precision medicine change the way we interact with patients?
- Who are the new healthcare influencers?
Five key trends in precision and personalised healthcare
|5th December 2019
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies can position themselves as leaders at the forefront of these exciting innovations.
Why aren't doctors using digital therapeutics?
|29th November 2019
The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these tools by healthcare professionals is comparatively low. Senior User Experience Consultant Stewart Anderson explains why.
Launch Excellence 2020
|18th November 2019
In this publication, we explore what makes a successful pharma launch from developing insight that drives behaviour change to lean launches and multi-indication launches, as well as an evaluation of the CAR-T market.